OxTalks is Changing
            
                On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
            
            
                There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
            
            
                If you have any questions, please contact halo@digital.ox.ac.uk
            
         
     
 
            
            
Functional plasticity of CD4+ T cells is driven by an asymmetric inheritance of mitochondria
    
	Steve Cobbold is Professor of Cellular Immunology at the Sir William Dunn School of Pathology, University of Oxford, where he continues to investigate how monoclonal antibodies can be used to therapeutically manipulate the immune system.  He studied Biochemistry in Oxford, followed by a Ph.D. in Cambridge, which led to the first demonstrations of tolerance induction to proteins and then organ grafts using CD4 monoclonal antibodies in adult rodents. As part of the Waldmann group, he was also actively involved in the development of CAMPATH monoclonal antibodies, which are now used for the treatment of certain leukemias and for multiple sclerosis. He also developed statistical methods for the analysis of antibody clusters as used in the 3rd Human CD Antigen Workshop (1987) and in 1993 he organized the first Canine Leukocyte Antigen Workshop (CLAW).  He was a scientific co-founder of TolerRx Inc., and together with Geoff Hale and Peppy Rebello, he co-founded BioAnaLab Ltd., a company that performs contract research and diagnostic testing for the biopharmaceutical industry, which was successfully sold to Merck/Millipore in 2009. He has published more than 250 articles and patents on the therapeutic applications of monoclonal antibodies and the mechanisms of transplantation tolerance. He recently suffered end stage renal failure and received a reciprocal paired donation kidney transplant with CAMPATH induction – perhaps the ultimate in clinical translation of his work?
Date:
18 January 2016, 12:00
Venue:
  Kennedy Institute of Rheumatology, Headington OX3 7FY
  
Venue Details:
  Bernard Sunley Lecture Theatre
  
Speaker:
  
    Prof Stephen Cobbold (University of Oxford)
  
    
Organising department:
    Kennedy Institute of Rheumatology
    
Organisers:
    
        Jo Silva (NDORMS), 
    
        Wulf Forrester-Barker (University of Oxford, Nuffield Dept of Orthopaedics Rheumatology and Musculoskeletal Sciences), 
    
        Molly Glaze (PA to Professor Michael Dustin ), 
    
        Gintare Kolesnikovaite (Kennedy Institute of Rheumatology)
    
    
Organiser contact email address:
    molly.glaze@kennedy.ox.ac.uk
    
Host:
    
        Prof Mike Dustin (PROFESSOR OF IMMUNOLOGY AND WELLCOME PRINCIPAL RESEARCH FELLOW, DIRECTOR OF RESEARCH OF THE KENNEDY INSTITUTE)
    
    
Part of:
    Kennedy Institute Seminars
Booking required?:
Not required
Audience:
Members of the University only
    
Editor: 
      Gintare Kolesnikovaite